<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>Rick Doblin on Podcast To Books</title><link>https://mcaneff.github.io/podcasts-to-books/guests/rick-doblin/</link><description>Recent content in Rick Doblin on Podcast To Books</description><generator>Hugo -- 0.145.0</generator><language>en</language><lastBuildDate>Fri, 09 May 2025 00:00:00 +0000</lastBuildDate><atom:link href="https://mcaneff.github.io/podcasts-to-books/guests/rick-doblin/index.xml" rel="self" type="application/rss+xml"/><item><title>#2319 - Rick Doblin</title><link>https://mcaneff.github.io/podcasts-to-books/joe-rogan/2319-rick-doblin/</link><pubDate>Fri, 09 May 2025 00:00:00 +0000</pubDate><guid>https://mcaneff.github.io/podcasts-to-books/joe-rogan/2319-rick-doblin/</guid><description>&lt;p>Rick Doblin, Ph.D., is the founder and president of the Multidisciplinary Association for Psychedelic Studies (MAPS), a nonprofit established in 1986 to advance evidence-based psychedelic therapy and end prohibition. MAPS incubated Lykos Therapeutics (formerly MAPS Public Benefit Corporation) which is leading drug development of MDMA-assisted therapy for PTSD. &lt;/p>
&lt;p>Learn more about Psychedelic Science 2025, June 16–20 at the Colorado Convention Center in Denver, at www.psychedelicscience.org, and visit www.maps.org for information on MAPS
Learn more about your ad choices.&lt;/p></description></item></channel></rss>